COMPLIANCE OF ANTHRAX RECOMBINANT VACCINE PROTOTYPE WITH THE REQUIREMENTS TO IMMUNE-BIOLOGICAL PREPARATIONS

Cover Page

Cite item

Abstract

Current areal of anthrax among live stock and wild animals covers almost all the continents. The cause of human infection is conventionally considered to be the contact with diseased animals in the process of carrying for an animal, forced slaughter or further trimming of carcasses, as well as contact with infected raw materials of animal origin. Licensed vaccines has made an invaluable contribution to the improvement of epidemiological situation on anthrax, however, development of the vaccines complying with current scientific progress remains relevant. We have constructed a vaccine prototype containing recombinant protective antigen and S-layer EA1 protein and added state-of-the-art CpG 2006 adjuvant to the formulation. We have demonstrated the advantage of the lyophilized form of the preparation. Objective — obtainment of anthrax vaccine prototype in lyophilized state and assessment of the prototype compliance with the requirements to vaccine preparations. Materials and methods. Isolation of rPA and EA1 protein was carried out using producer-strain B. anthracis 55ΔTПА-1Spo– on an integrated end-to-end manufacturing line, including concentration, diafiltration and two-phase chromatography. CpG 2006 adjuvant was synthesized according to known sequences. Components were mixed and lyophilized in sublimation unit. Combination of 1% sucrose and 3% glycine was used as cryoprotector. Effectiveness and safety of the preparation were evaluated on the model of BALB/c mice and guinea pigs applying immunological, morphometric, and histological assays. Antibody titers in sera of immunized animals were evaluated using standard ELISA procedures. Protective properties were investigated through LD50 values for the test-strain used on immunized and control animals and immunity index. Results. We have performed complex investigation of the anthrax vaccine prototype, containing B. anthracis 55ΔTПА-1Spo– proteins as main and supplementary antigens, as well as CpG 2006 adjuvant, stabilizers and preservative agent. The prototype meets the requirements to immunobiological medicinal drugs by all physical-chemical properties. Our preparation does not have a toxic effect on the organism of laboratory animals in case of subcutaneous and intraperitoneal administration of single human dose. Pathomorphological study of guinea pigs’ organs immunized with double dose of the vaccine prototype has not revealed any evidence of damaging effect on the cells and tissues of macroorganism. The prototype protects BALB/c mice from the infection with B. anthracis 71/12 test-strain.

About the authors

N. I. Mikshis

Russian Research Anti-Plague Institute “Microbe”.

Author for correspondence.
Email: Mikshis_N@mail.ru

PhD, MD (Medicine), Leading Researcher of Immunology Department.

410005, Russian Federation, Saratov, Universitetskaya str., 46.

Phone: +7 (8452) 26-21-31 (office).

Russian Federation

A. P. Semakova

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD (Biology), Senior Research Officer of the Department of Experimental Animals with Vivarium.

Saratov. Russian Federation

P. Yu. Popova

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD (Medicine), Senior Researcher of Immunology Department.

Saratov. Russian Federation

O. M. Kudryavtseva

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD (Medicine), Senior Research Officer of Immunology Department.

Saratov. Russian Federation

S. A. Bugorkova

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD, MD (Medicine), Chief Research Officer, Head of Immunology Department.

Saratov. Russian Federation

A. V. Komissarov

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD, MD (Medicine), Associate Professor, Head of the Department of Experimental Pharmaceutical Forms.

Saratov. Russian Federation

V. G. Germanchuk

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD, MD (Medicine), Associate Professor, Head of the Department of Experimental Animals with Vivarium.

Saratov. Russian Federation

Yu. A. Popov

Russian Research Anti-Plague Institute “Microbe”.

Email: fake@neicon.ru

PhD, MD (Medicine), Professor, Head of the Department of Educational Programmes and Training of Specialists.

Saratov. Russian Federation

References

  1. Государственная Фармакопея Российской Федерации. 12-е изд. Часть 1. М.: Научный центр экспертизы средств медицинского применения, 2008. 704 с.
  2. Коржевский Д.Э., Гиляров А.В. Основы гистологической техники. М.: СпецЛит., 2010. 96 с.
  3. Микшис Н.И., Попова П.Ю., Семакова А.П., Кудрявцева О.М., Бугоркова С.А., Кравцов А.Л. Изучение влияния антигенов, полученных из рекомбинантного штамма B. anthracis 55ΔTПА-1Spo-, на органы и ткани иммунизированных животных // Биотехнология. 2017. Т. 33, № 5. С. 45–60.
  4. МУК 4.1/4.2.588-96. Методы контроля медицинских иммунобиологических препаратов, вводимых людям. М.: 1996. 88 с.
  5. Попова А.Ю., Демина Ю.В., Ежлова Е.Б., Куличенко Н.К., Рязанова А.Г., Малеев В.В., Плоскирева А.А., Дятлов И.А., Тимофеев В.С., Нечепуренко Л.А., Харьков В.В. Вспышка сибирской язвы в Ямало-Ненецком автономном округе в 2016 г., эпидемиологические особенности // Проблемы особо опасных инфекций. 2016. № 4. С. 42–46.
  6. Семакова А.П., Кудрявцева О.М., Попова П.Ю., Комиссаров А.В., Микшис Н.И. Стабилизация путем лиофилизации иммуногенных антигенов Bacillus anthracis в составе прототипа рекомбинантной вакцины против сибирской язвы // Биотехнология. 2017. Т. 33, № 3. С. 57–65.
  7. Семенов Б.Ф., Зверев В.В., Хаитов Р.М. Прогноз развития вакцинопрофилактики в первые десятилетия XXI века // Иммунология. 2009. № 6. С. 324–335.
  8. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines, 2011, vol. 10, no. 4, рр. 499–511. doi: 10.1586/erv.10.174
  9. Kristensen D., Chen D. Stabilization of vaccines: lessons learned. Hum. Vaccines, 2003, no. 6, рр. 229–231.
  10. Minang J., Inglefield J., Harris A., Lathey J.L., Alleva D.G., Sweeney D.L., Hopkins R.J., Lacy M.J., Bernton E.W. Enhanced early innate and T cell-mediated responses in subjects immunized with anthrax vaccine adsorbed plus CPG 7909 (AV7909). Vaccine, 2014, vol. 32, no. 50, рр. 6847–6854. doi: 10.1016/j.vaccine.2014.01.096
  11. Williamson E., Dyson E. Anthrax prophylaxis recent advances and future directions. Front. Microbiol., 2015, vol. 6: e1009. doi: 10.3389/fmicb.2015.01009

Copyright (c) 2018 Mikshis N.I., Semakova A.P., Popova P.Y., Kudryavtseva O.M., Bugorkova S.A., Komissarov A.V., Germanchuk V.G., Popov Y.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies